Cardiac Rehabilitation, Valve Disease, Aortic
Conditions
Keywords
transcatheter aortic valve implantation, cardiac rehabilitation, cardiopulmonary function
Brief summary
Cardiac rehabilitation (CR), particularly regular exercise, can improve the cardiopulmonary function, exercise capacity, and quality of life for patients undergoing transcatheter aortic valve implantation (TAVI). Consequently, the patients after TAVI will be enrolled in our randomized controlled trial to demonstrate if the moderate-intensity continuous training (MICT) can improve the cardiopulmonary function compared with the control group after receiving treatment for 12 weeks. Moreover, we will provide new insights regarding whether cardiac systolic function or cardiac diastolic function is mainly improved after regular exercise for TAVI patients. As a result, the principal hypothesis of our study is that MICT will improve the cardiopulmonary function and can extremely affect the cardiac diastolic function of patients with TAVI after the implementation of exercise for 12 weeks.
Interventions
BEHAVIORALmoderate intensity continuous training
Moderate intensity continuous training was scheduled 3 times per week for 3 months. Every sessions included warm-up (\<50% target intensity for 2 min then gradually increasing load 1-10 W/min up to 100% target intensity for 5-10 min), exercise phase (100% target intensity (heart rate at anaerobic threshold±5) starting with 20 min and gradually lengthening up to 45 min in the 1 month as well as 45 min in another 2 months), cool down with gradual reduction of load within 3 min. The target intensity will be determined by the heart rate at anaerobic threshold measured by cardiopulmonary exercise test (CPET). The intensity will be adjusted after implementation of CPET and will keep at a minimum intensity, gradually increasing to the maximum intensity every month. Moreover, patients will be instructed to complete 2 supervised sessions and 1 home-based session during the 1 month and then to continue 3 home-based session for a further 2 months.
Sponsors
Han Yaling, MD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* TAVI after 1 month * able to start cardiac rehabilitation(CR) as judged by the study investigators * age \>18 years old * 6-min walk distance (6MWD) ≥100m * patients able to provide the informed consent before randomization
Exclusion criteria
* exercise-limiting comorbidities such as primarily orthopedic, neurological conditions that would exclude the patients from participating in CR * linguistic deficits * patient unwilling or unable to provide written informed consent * patients with acute systemic diseases e.g. hyperthyroidism, electrolyte disturbances, uncontrolled diabetes, hemoglobin\< 9 g/dL, uncontrolled asthma, severe obstructive pulmonary disease (forced expiratory volume in 1 second\<50%), respiratory failure, and pulmonary embolism * echocardiographic signs of prosthesis dysfunction including valve orifice area of \<1.2 cm2 plus a mean transaortic pressure gradient of ≥20 mmHg, or a velocity of ≥3 m/s, at least moderate paravalvular regurgitation, signs of ischemia, severe arrhythmias, or hemodynamic deterioration during the exercise test * decompensated heart failure (New York Heart Association (NYHA) class IV) * patients with irreversible atrial or ventricular arrhythmias or patients with severe atrioventricular block * bradycardia (heart rate\<60bpm) or patients who need implantation of a pacemaker or implantable cardioverter defibrillators (ICD) * recent history of sudden cardiac death syndrome * suspected aortic dissection, pericarditis, hypertrophic obstructive cardiomyopathy and subacute bacterial endocarditis * untreated or uncontrolled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \>110 mmHg) or hypotension (systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<60mmHg) * cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism or other brain disease history * active or recent major bleeding or bleeding predisposition * coronary artery bypass grafting (CABG) within 3 months * renal insufficiency (serum creatinine \>2.5 mg/dl) * planning to, or participation in another intervention study within 3 months * patients with exercise intolerance or poor exercise endurance * patients who are currently receiving systematic training * researchers think it is not suitable to participate in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in peak oxygen uptake (peak VO2) after 3 months | 3 months and 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the Medical Outcomes Study 12-Item Short-Form Health Survey (SF-12) | 3 months and 1 year | — |
| New York Heart Association class (NYHA) | 3 months and 1 year | The NYHA is measured by Classification of NYHA heart function |
| E/e' | 3 months and 1 year | it is measured by echocardiography |
| E/A | 3 months and 1 year | it is measured by echocardiography |
| left atrial volume index(LAVI) | 3 months and 1 year | it is measured by echocardiography |
| left ventricular ejection fraction(LV-EF) | 3 months and 1 year | it is measured by echocardiography |
| mean pressure gradient(PGmean) | 3 months and 1 year | it is measured by echocardiography |
| maximal pressure gradient (PGmax) | 3 months and 1 year | it is measured by echocardiography |
| maximal velocity(Vmax) | 3 months and 1 year | it is measured by echocardiography |
| 6-min walk distance | 3 months and 1 year | — |
| N-terminal pro-brain natriuretic peptide (NT-proBNP) | 3 months and 1 year | — |
| C-reactive protein(CRP) | 3 months and 1 year | — |
| hemoglobin | 3 months and 1 year | — |
| cholesterol | 3 months and 1 year | — |
| triglyceride | 3 months and 1 year | — |
| high density lipoprotein (HDL) | 3 months and 1 year | — |
| low density lipoprotein (LDL) | 3 months and 1 year | — |
| Major adverse cardiovascular events | 3 months and 1 year | Major adverse cardiovascular events is a composite endpoint of death, stroke, revascularization, and myocardial infarction. |
| change in peak oxygen uptake (peak VO2) after 1 year | 1 year | — |
| valve orifice area | 3 months and 1 year | it is measured by echocardiography |
Countries
China
Contacts
Primary ContactYa-Ling Han, PhD
Outcome results
None listed